Cases and resources in vascular techniques

Dr Mallios welcomes Dr Lucas to share practical tips for creating successful distal AV fistulas, from vein selection and surgical techniques to patient selection and outcomes. The discussion covers snuffbox fistulas, technical refinements and strategies to optimise maturation and patency.

Drug-coated technologies must demonstrate lasting clinical benefits beyond improved vessel patency, with patient outcomes, long-term durability and cost-effectiveness guiding future treatment decisions.

Explore how drug-coated balloons, drug-eluting stents and vessel preparation guide peripheral revascularisation, from femoropopliteal disease and in-stent restenosis to chronic limb-threatening ischaemia, and where evidence gaps remain.

From mechanical scaffolding to drug-coated technologies, peripheral intervention has evolved towards a more biology-driven approach. Yet improved vessel patency alone is not enough: the next frontier is to tailor treatment to the lesion and patient, and demonstrate that greater vascular durability translates into meaningful clinical benefits.

Drug-coated technologies have transformed femoropopliteal intervention, but their benefits below the knee remain uncertain. This article reviews the evidence on paclitaxel safety, emerging sirolimus-based alternatives and resorbable scaffolds for infrapopliteal disease.

What is "fake news" in vascular access? Dr Alexandros Mallios and Dr Nick Inston discuss common misconceptions, the limitations of current evidence, and the importance of balancing and combining guidelines with clinical judgement to select the most appropriate access for each patient.

Dr Caitlin Hicks and Dr Gustavo Basso discuss personalised carotid revascularisation, exploring CREST-II, T-CAR, plaque assessment using hand-held ultrasound devices (HUDs), and emerging stent technologies. The interview also examines treatment strategies for asymptomatic carotid stenosis and acute stroke.

Dr Massara and Prof Ducasse discuss aortic arch repair, covering patient selection, endovascular and hybrid strategies, fenestrated endografts, procedural considerations and clinical cases involving aortic arch and descending thoracic aortic aneurysms.

Recurrent iliac in-stent thrombosis and an atheromatous aortic bifurcation make the next move anything but straightforward. Which strategy would you choose?

In this article, explore the cost-effectiveness and budget impact of drug-coated technologies in PAD, from intermittent claudication to CLTI, and the economic challenges shaping current practice and future research.